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Diabetic peripheral neuropathy (DPN) is a serious and 
common chronic complication of diabetes mellitus, with 
up to half of the sufferers’ developing chronic neuropathic 
pain (painful-DPN). Unfortunately, our understanding 
of the pathophysiology of both painless- and painful-
DPN remains inadequate. Consequently, we currently 
have no efficacious disease modifying therapies for either 
condition, apart from robust evidence for good glycaemic 
control in preventing DPN in patients with type 1 diabetes. 
Neuronal injury in DPN has been well recognised within 
the peripheral nervous system for over a century. Studies in 
the 1960’s identified pathological alterations in spinal cord 
and brain structures in patients with diabetes and advanced 
microvascular complications (1,2). However, for many years 
after these findings, the involvement of central nervous 
system (CNS) in DPN was largely overlooked until the 
advent of advanced neuroimaging techniques in the latter 
part of the 20th century. 
Magnetic resonance imaging (MRI) is able to non-
invasively investigate not only the gross structure, but 
the micro-structure, function and vascular supply of 
the brain. MRI studies have demonstrated a number of 
structural abnormalities, including spinal cord atrophy (3) 
and grey matter volume reduction (4) as well as functional 
abnormalities, including thalamic neuronal dysfunction (5), 
increased thalamic vascularity (6), altered thalamo-cortical 
connectivity (7) and functional reorganization of the 
somatosensory cortex (8), associated with DPN. 
In a recent publication Zhang et al. studied 44 patients 
with type 2 diabetes and painless-DPN, 23 patients with 
painful-DPN and 88 healthy control subjects without 
diabetes (9). Compared to healthy controls, patients with 
DPN had abnormalities in the pre- and post-central 
gyrus and a number of deep grey matter nuclei. They 
also demonstrated altered white matter tracts including 
corticospinal, spinothalamic and thalamo-cortical projecting 
fibres. They concluded that these findings suggest impaired 
motor and somatosensory pathways in DPN. In this study 
the presence of peripheral neuropathy was confirmed using 
detailed upper and lower limb neurological examination, 
nerve conduction testing and a battery of quantitative 
sensory testing measures, as well as symptoms and clinical 
signs. According to Toronto consensus (10) “confirmed” 
neuropathy is diagnosed in the presence of abnormal nerve 
conduction and the group appear to have adhered to this 
recommendation; however, both the painless- and painful-
DPN groups had at best very mild peripheral neuropathy 
with almost normal peroneal and sural nerve amplitudes 
and nerve conduction velocities. Moreover, the neuropathy 
disability score was less than 3 in both the painful- and 
painless-DPN groups, again indicating almost subclinical-
DPN. Thus, given the early neuropathy features of these 
DPN groups the demonstration of significant structural 
abnormalities in the brain does raise the possibility that the 
insult of hyperglycaemia/vascular risk factors associated with 
diabetes may concomitantly affect both the PNS and CNS. 
When the discovery of spinal cord atrophy in DPN was first 
demonstrated the assumption was that this was secondary 
to distal axonopathy (‘dying back phenomenon’) (11). 
However, a further larger study including subjects with 
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subclinical-DPN demonstrated involvement of the spinal 
cord, indicating that this process is very early or possibly 
concomitant to peripheral nerve injury (3). We know that 
diabetes affects the autonomic nervous system, corneal 
nerve fibres and cranial nerves. The impact of diabetes on 
the nervous system could therefore be more generalized, 
affecting both the periphery and CNS at the same time.
Although the study by Zhang et al. does point to 
significant CNS abnormalities in both painless- and painful-
DPN, the natural history of these needs further examination 
in the context of a longitudinal study (9). This will give 
us insight into the direction of causality and pathological 
processes underlying cerebral involvement. The addition 
of a diabetes group without neuropathy as well as a disease 
control group of subjects with a non-DPN may be useful 
in identifying the diabetes effect and a generic neuropathy 
effect on the brain. Moreover, although there may be 
technical difficulties in conducting multiple MR techniques 
at the same time in the same subject, there is clearly a need 
to study both structure and function components at the 
same time. For example, we need to understand why there 
is a reduction in somatosensory peripheral grey matter 
volume (4). What are the potential mechanisms for this? It 
might be possible that these patients may have abnormal 
regional blood perfusion or a reduction in neuronal activity 
because of altered peripheral and long-tract neuronal 
function. Considerable insight could be gained from MR 
perfusion imaging, including dynamic susceptibility contrast 
and arterial spin labelling (12). MR proton spectroscopy 
could provide information into neuronal function (5) and 
changes in neurotransmitter (e.g., GABA) levels (13) within 
regions of interest in the brain. Furthermore, functional 
MR imaging, either in the resting state of task-based - such 
as blood oxygen dependent (BOLD) (7,8) could be used 
inform areas of altered activity in carefully characterised 
and phenotyped patients with or without DPN. Although 
technically challenging, with the use of higher field strength 
MR scanners functional spinal cord imaging may become 
feasible to characterise involvement of spinal involvement 
in DPN. In addition, MR imaging has been largely used for 
the study of peripheral rather than autonomic neuropathy in 
diabetes; however, cardiac MR could be used to investigate 
the effect of diabetic cardiac autonomic neuropathy 
on cardiac haemodynamics. Other imaging modalities 
have been favoured for the investigation of autonomic 
neuropathy, e.g., PET/MIBG. Future studies need to be 
designed to be adequately powered, randomised, controlled 
and if possible in a multicentre setting, using standardised 
imaging parameters. This is likely to make the findings 
generalizable. Moreover, there is recent evidence that 
DPN may have different underlying disease mechanisms in 
type 1 compared with type 2 diabetes. Therefore, studies 
must control for the type of diabetes. Investigation into 
the CNS alterations between type 1 and type 2 diabetes is 
important too, as it is unknown as to whether structural 
and functional alterations differ between types of diabetes. 
The involvement of CNS in DPN, hitherto considered a 
“purely peripheral neuropathy” (14), has opened a whole 
new area for further research and has a great potential for 
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